RNS Number: 3880 Q Immupharma PLC 18 June 2020. 2020 ANNUAL GENERAL MEETING- ALL RESOLUTIONS PASSED. ImmuPharma PLC, the specialist drug discovery and development company, held its AGM earlier today, in accordance with COVID-19 guidance.
RNS Number: 0027 Q Immupharma PLC 16 June 2020 RNS| eCorporate 16 June 2020. ImmuPharma PLC,, the specialist drug discovery and development company announces that in accordance with its obligations to the Company's Euronext listing and following an application of Article 15 of the Belgian Law of 2 May 2007, the total number of shares with voting rights and the...
Immupharma Plc (IMM.L) Announced that it has entered into agreements with two specialist US healthcare investors for a total investment of up to $6.30 million (£4.94 million) comprising an issue of unsecured convertible securities and associated options. ImmuPharma is to issue $3.00 million (£2.35 million) in face value of Securities to two US specialist healthcare investors, L1 Capital Global Opportunities Master Fund and Lind Global Macro Fund LP, managed by The Lind Partners, LLC with a maturity period of 18 months. #IMM
RNS Number: 6729 P Immupharma PLC 11 June 2020. ImmuPharma announces that on 11 June 2020, Dr Robert Zimmer, a Director of the Company, transferred 20,000,000 ordinary shares of 10 pence each to Luca& Associates AG, an entity connected with Dr Zimmer, and of which he is President and a shareholder. RNS is approved by the Financial Conduct Authority to act as a Primary...
ImmuPharma PLC, the specialist drug discovery and development company, is pleased to announce that it has entered into agreements with two specialist US healthcare investors for a total investment of up to $6.30 million comprising an issue of unsecured convertible securities and associated options. ·In addition, the Investors have been granted 15,703,942...
RNS Number: 9805 O Immupharma PLC 05 June 2020 RNS: FOR IMMEDIATE RELEASE 5 June 2020. Notification of Change of Registered Office Address. ImmuPharma PLC,, the specialist drug discovery and development company announces that with immediate effect, its registered office address has been changed to: One Bartholomew Close, London, EC1A 7 BL..
RNS Number: 5931 O Immupharma PLC 02 June 2020 RNS: FOR IMMEDIATE RELEASE 2 June 2020. Notification of Change of AGM Venue. ImmuPharma PLC,, the specialist drug discovery and development company announces that the Company's Annual General Meeting confirmed for Thursday, 18 June 2020@ 10.30 am, will now be held at: 52 Grosvenor Garden, London SW1W 0 AU..
RNS Number: 5047 N Immupharma PLC 21 May 2020. RNS: RELEASE 21 MAY 2020. Notice of AGM and posting of Report& Accounts.
RNS Number: 2357 N Immupharma PLC 18 May 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
ImmuPharma 19.6p £32.6m (IMM.L) Notes the results of a recent study conducted at Emory University Atlanta GA, suggesting that Covid-19 (SARS-COV-2) patients and systemic lupus erythematosus (SLE) patients experiencing flares might share similar inflammatory symptoms, underpinned by similar mechanisms (role of cytokines). Lupuzor ™ is a modulator of the immune response and an anti-inflammatory agent, which has activity against SLE (lupus), an autoimmune disease, as well as against other inflammatory diseases. ImmuPharma, together with its US licencing partner, Avion Pharmaceuticals, will be progressing Lupuzor ™ into a new optimised international Phase III trial this year in lupus patients. #IMM
Immupharma Plc #IMM Announced an update on activities around Covid-19. On 30 March 2020, ImmuPharma announced that it had expanded its pipeline to include three new 'Anti-Infective' programs, one of which was in 'Antivirals'. Investigation of the application of the Ureka peptide technologies within this Antivirals program suggests the potential to create effective anti-fusion peptides with the goal to prevent virus entry into the host cells, which may lead to novel peptide based antiviral therapies. Further exploratory work continues on this program. In additions, ImmuPharma, together with its US licencing partner, Avion Pharmaceuticals, will be progressing LupuzorTM into a new optimised international Phase III trial this year in lupus patients.
RNS Number: 8372 M Immupharma PLC 14 May 2020. RNS: FOR IMMEDIATE RELEASE 14 May 2020. ImmuPharma's efforts in the fight against Covid-19 with Lupuzor™ and Ureka.
RNS Number: 4797 L Immupharma PLC 30 April 2020 RNS: RELEASE 30 April 2020. Audited Report& Accounts published on website. ImmuPharma PLC,, the specialist drug discovery and development company confirms that the Audited Annual Report and Accounts for the year ended 31 December 2019, has today been published on the Company's website.
o Cash balance of £1.4 million. o Loss for the period of £6.1 million. o Research and development expenses of £2.7 million.
RNS Number: 7844 I Immupharma PLC 06 April 2020 6 April 2020. ImmuPharma to present live on' Investor Meet Company' platform Tuesday 7 April 2020| 10.30 am. ImmuPharma PLC, a specialist drug discovery and development company, is pleased to announce that Tim McCarthy, Chairman of ImmuPharma, will provide a live presentation relating to the recently announced £1.5...
RNS Number: 7926 I Immupharma PLC 03 April 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 5535 I Immupharma PLC 02 April 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 2948 I Immupharma PLC 31 March 2020. A second and final Price Monitoring Extension has been activated in this security. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 2916 I Immupharma PLC 31 March 2020. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
ImmuPharma Plc
IMM.L
ImmuPharma Plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    167.39M

Featured Media

Company Profile

ImmuPharma PLC is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by High unmet medical need Low marketing costs Relatively low development costs Founded first in Basel, Switzerland in 1999 and led by an experienced management team, ImmuPharma now has important R&D collaboration arrangements with highly respected health and medical research laboratories in Europe. The company plans either to bring its drug candidates to market itself, or to license them in corporate deals to other pharmaceutical companies.

Classification

Market Indices-
Watchlist